
Initiation of Coverage Pharmiva: Launch Should Provide Positive Momentum

Carlsquare Equity Research initiates coverage of Pharmiva with a positive view on the launch of the infection treatment Vernivia. We see good prospects of expected news flow and gradual roll-out to more geographic markets supporting the shares.

[Read the report here.](#)

About Carlsquare

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team have an extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Berlin, Copenhagen, Hamburg, London, Munich and Stockholm. [Read more](#)

Contact

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON

Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

JONATAN ANDERSSON

Equity Analyst
jonatan.andersson@carlsquare.com
+46 (0)70 508 00 51

Attachments

[Initiation of Coverage Pharmiva: Launch Should Provide Positive Momentum](#)